Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs MEDI-1341 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Oct 2018 Planned End Date changed from 26 Sep 2019 to 6 Nov 2019.
    • 17 Oct 2018 Planned primary completion date changed from 26 Sep 2019 to 6 Nov 2019.
    • 06 Aug 2018 Planned End Date changed from 18 Oct 2018 to 26 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top